Cortexyme (CRTX) Stock Price, News & Analysis

Company Overview

Cortexyme, Inc. is a clinical-stage biotechnology company focused on the development of treatments for Alzheimer’s disease and other chronic conditions associated with bacterial proteases. The company’s research centers on targeting virulence factors produced by the oral pathogen Porphyromonas gingivalis, an organism increasingly implicated in neurodegeneration. By inhibiting the activity of gingipains—proteolytic enzymes secreted by P. gingivalis—Cortexyme aims to reduce inflammation and tissue damage in the brain and other organs.

The company’s lead product candidate, atuzaginstat (COR388), is a small-molecule inhibitor designed to cross the blood–brain barrier and neutralize gingipain activity. Atuzaginstat has advanced through Phase 1 safety studies and into multiple Phase 2 trials assessing its ability to slow cognitive decline in patients with mild to moderate Alzheimer’s disease. In addition to its Alzheimer’s program, Cortexyme is exploring the potential of gingipain inhibition in other chronic inflammatory conditions where P. gingivalis may play a role.

Founded in 2016 and headquartered in San Francisco, California, Cortexyme combines expertise in microbiology, neuroscience and medicinal chemistry. The company collaborates with academic institutions and clinical research organizations in North America and Europe to conduct biomarker analyses and clinical trials. Its multidisciplinary team of scientists and clinicians aims to validate a new therapeutic approach that addresses one of the hypothesized infectious contributors to neurodegeneration.

As a biotechnology innovator, Cortexyme leverages proprietary chemistry platforms and translational research to identify and advance oral pathogen–targeted therapeutics. With a focus on safety, efficacy and biomarker-driven clinical development, the company seeks to establish gingipain inhibition as a novel mechanism for treating Alzheimer’s disease and potentially other degenerative disorders linked to chronic bacterial infection.

Key Stats

• Today's Range: $1.58 to $1.62
• 50-Day Range: $1.54 to $1.90
• 52-Week Range: $1.78 to $40.66
• Volume: 133,052 shs
• Average Volume: 620,672 shs
• Market Capitalization: $48.24 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CRTX Stock Analysis - Frequently Asked Questions

How have CRTX shares performed this year?

Cortexyme's stock was trading at $1.85 on January 1st, 2025. Since then, CRTX stock has decreased by 13.5% and is now trading at $1.60.

How were Cortexyme's earnings last quarter?

Cortexyme, Inc. (NASDAQ:CRTX) announced its quarterly earnings results on Monday, August, 9th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.79) by $0.05.

When did Cortexyme IPO?

Cortexyme (CRTX) raised $75 million in an IPO on Thursday, May 9th 2019. The company issued 4,400,000 shares at $16.00-$18.00 per share. BofA Merrill Lynch and Credit Suisse acted as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.

How do I buy shares of Cortexyme?

Shares of CRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cortexyme own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cortexyme investors own include Alibaba Group (BABA), Enterprise Products Partners (EPD), NVIDIA (NVDA), Tesla (TSLA), Pfizer (PFE), Meta Platforms (META) and AT&T (T).

Company Calendar

• Last Earnings: 8/09/2021
• Today: 9/15/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological Products, Except Diagnostic
• Sub-Industry: Health Care Technology
• Current Symbol: NASDAQ:CRTX
• CIK: 1145404
• Web: www.cortexyme.com
• Phone: (650) 910-5717
• Fax: N/A
• Employees: 55
• Year Founded: 2012

Profitability

• EPS (Trailing Twelve Months): ($2.97)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$89.94 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -70.96%
• Return on Assets: -63.53%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.92
• Quick Ratio: 9.92

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.97 per share
• Price / Book: 0.40

Miscellaneous

• Outstanding Shares: 30,151,000
• Free Float: 21,739,000
• Market Cap: $48.24 million
• Optionable: Not Optionable
• Beta: 1.40